Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10081625 5-methyl-1,2,4-oxadiazol-3-yl compounds

Patent 10081625 was granted and assigned to Eli Lilly and Company on September, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Eli Lilly

Current Assignee

Eli Lilly

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10081625

Date of Patent

September 25, 2018

Patent Application Number

15874947

Date Filed

January 19, 2018

Patent Citations Received

‌

US Patent 11999726 5-methyl-4-fluoro-thiazol-2-yl compounds

‌

US Patent 10752632 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds

‌

US Patent 10836773 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

‌

US Patent 11839654 Combination therapy

‌

US Patent 10377750 5-methyl-1,3,4-oxadiazol-2-yl compounds

Patent Primary Examiner

‌

Rita J Desai

Patent abstract

The present invention provides a compound of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10081625 5-methyl-1,2,4-oxadiazol-3-yl compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API